Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1. (Currently amended) A method of modulating an endothelial gene differentiation-1 ("Edg-1") ~~Edg-1~~ receptor mediated ~~biological activity~~ for vasoconstriction, comprising contacting a cell expressing the Edg-1 receptor with an amount of a non-phospholipid modulator of the Edg-1 receptor sufficient to modulate the Edg-1 receptor mediated ~~biological activity~~ for vasoconstriction, ~~wherein the modulator is not a phospholipid.~~ wherein said modulator is a compound of Formula (Ia):



(Ia)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;

R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

each R^2, R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and

each R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

2. (Currently amended) A method of modulating an Edg-1 receptor mediated ~~biological activity~~ for vasoconstriction in a subject, comprising administering to the subject a therapeutically effective amount of a non-phospholipid modulator of the Edg-1 receptor, ~~wherein the modulator is not a phospholipid.~~ wherein said modulator is a compound of Formula (Ia):



(Ia)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein:

n is a member selected from the integers 0 to 5;

R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

each R^2, R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and

each R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

3. (Canceled)

4. (Original) The method of Claim **1** or **2**, wherein the modulator is an antagonist.

5. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 200 fold inhibitory selectivity for Edg-1 relative to ~~other Edg~~ Edg-2, Edg-4 and Edg-7 receptors.

6. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 100 fold inhibitory selectivity for Edg-1 relative to ~~other Edg~~ Edg-2, Edg-4 and Edg-7 receptors.

7. (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits at least about 20 fold inhibitory selectivity for Edg-1 relative to ~~other Edg~~ Edg-2, Edg-4 and Edg-7 receptors.

8. (Currently amended) The method of Claim **1** or **2**, wherein the ~~inhibitor~~ modulator exhibits at least about 5 fold inhibitory selectivity for Edg-1 relative to ~~other Edg~~ Edg-2, Edg-4 and Edg-7 receptors.

9. (Currently amended) The method of Claim **1** or **2**, wherein the ~~inhibitor~~ modulator exhibits at least about 200 fold inhibitory selectivity for Edg-1 relative to Edg-3, Edg-5, Edg-6 and Edg-8 receptors.

10. (Currently amended) The method of Claim **1** or **2**, wherein the ~~inhibitor~~ modulator exhibits at least about 100 fold inhibitory selectivity for Edg-1 relative to Edg-3, Edg-5, Edg-6 and Edg-8 receptors.

11. (Currently amended) The method of Claim **1** or **2**, wherein the ~~inhibitor~~ modulator exhibits at least about 20 fold inhibitory selectivity for Edg-1 relative to Edg 3, Edg-5, Edg-6 and Edg-8 receptors.

12. (Currently amended) The method of Claim **1** or **2**, wherein the ~~inhibitor~~ modulator exhibits at least about 5 fold inhibitory selectivity for Edg-1 relative to Edg-3, Edg-5, Edg-6 and Edg-8 receptors.

13. (Withdrawn) The method of Claim **1** or **2**, wherein the biological activity is cell proliferation.

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Withdrawn, Currently amended) The method of Claim **13**, wherein cell proliferation leads to cancer selected from the group consisting of ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colon cancer ~~or~~ and prostrate cancer.

19. (Withdrawn) The method of Claim **13**, wherein cell proliferation is stimulated by S1P.

20. (Canceled)

21. (Currently amended) The method of Claim **1** or **2** wherein the modulator binds to the Edg-1 receptor with a binding constant between about 1 femtomolar to about 10 μM ~~to about 1 fM~~.

22. (Original) The method of Claim **1** or **2** wherein the modulator binds to the Edg-1 receptor with a binding constant of at least about 1 μM.

23. (Original) The method of Claim **1** or **2** wherein the modulator binds to the Edg-1 receptor with a binding constant of at least about 10 nM.

24. (Withdrawn) The method of Claim **1** or **2**, wherein the modulator is a nucleic acid, peptide or carbohydrate.

25. (Original) The method of Claim **1** or **2**, wherein the modulator is an organic molecule of molecular weight of less than 750 daltons.

26. (Withdrawn, Currently amended) The method of Claim **1**, wherein the cell is a member selected from the group consisting of a HTC hepatoma cell, an ovarian cell, an epithelial cell, a fibroblast cell, a neuronal cell, a carcinoma cell, a pheochromocytoma cell, a myoblast cell, a platelet cell ~~or~~ and a fibrosarcoma cell.

27. (Withdrawn, Currently amended) The method of Claim **21**, wherein the cell is a member selected from the group consisting of OV202 human ovarian cell, a HTC rat hepatoma cell, a CAOV-3 human ovarian cancer cell, MDA-MB-453 breast cancer cell, MDA-MB-231 breast cancer cell, HUVEC cells A431 human epitheloid carcinoma cell ~~or~~ and a HT-1080 human fibrosarcoma cell.

28. (Canceled)

29. (Withdrawn, Currently amended) ~~The method of Claim 1 or 2,~~ A method of modulating an Edg-1 receptor mediated biological activity, comprising contacting a cell expressing the Edg-1 receptor with an amount of a non-phospholipid modulator of the Edg-1 receptor sufficient to modulate the Edg-1 receptor mediated biological activity, wherein the modulator is a compound of ~~structural formula~~ Formula (II):



(II)

or a pharmaceutically ~~available~~ acceptable solvate or hydrate thereof, wherein:

X is a member selected from the group consisting of O ~~or~~ and S;

each R^1, R^2, R^3, R^4 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro ~~or~~ and thio; and

each R^6, R^7, R^8, R^9 and R^{10} is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino,

arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro ~~or~~ and thio.

30. (Withdrawn, Currently amended) ~~The method of Claim 1 or 2,~~ A method of modulating an Edg-1 receptor mediated biological activity, comprising contacting a cell expressing the Edg-1 receptor with an amount of a non-phospholipid modulator of the Edg-1 receptor sufficient to modulate the Edg-1 receptor mediated biological activity, wherein the modulator is a compound of ~~structural formula~~ Formula (III):



(III)



(III)

or a pharmaceutically ~~available~~ acceptable solvate or hydrate thereof, wherein:

n is a member selected from the integers 1 to 4 ~~1, 2, 3, 4 or 5~~;

m is a member selected from the integers 1 to 4 ~~1, 2, 3, 4, or 5~~;

each X and Y is a member independently selected from the group consisting of C ~~or~~ and N; and

each R^1, R^2, R^3, R^4 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro ~~or~~ and thio.

31. (Withdrawn, Currently amended) A method for treating ~~or preventing~~ a disease or condition selected from the group consisting of cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, ~~or~~ and cardiovascular diseases in a subject in need of such treatment, said method comprising administering to ~~a~~ said subject ~~in need of such treatment or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formulae (I), (II) or (III).

32. (Withdrawn, Currently amended) A method for treating ~~or preventing~~ a disease or condition selected from the group consisting of ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer, prostrate cancer, adult respiratory distress syndrome (ARDS), asthma,

transcorneal freezing, cutaneous burns, ischemia ~~or~~ and atherosclerosis in a subject in need of such treatment, said method comprising administering to ~~a~~ said ~~subject in need of such treatment or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formulae (I), (II) or (III).

33. (Canceled)

34. (Currently amended) A method for treating ~~or preventing~~ vasoconstriction in cerebral arteries~~, systematic lupus erythematosus, rheumatoid arthritis, non-glomerular nephrosis, psoriasis, chronic active hepatitis, ulcerative colitis, Crohn's disease, Behget's disease, chronic glomerulonephritis, chronic thrombocytopenic purpura, autoinunune hemolytic anemia, migraine headache, stroke, subarachnoid hemorrhage, or a vasospasm~~ in a subject in need of such treatment, said method comprising administering to ~~a~~ said subject ~~in need of such treatment or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formula (Ia), ~~(II) or (III).~~ wherein said compound of Formula (Ia) is:



(Ia)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;

R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted

arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

each R^2, R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and

each R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

35. (Currently amended) A method for treating ~~or preventing cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, cardiovascular diseases,~~ vasoconstriction~~, autoimmune disorders or vascular occlusive disorders~~ in a subject in need of such treatment, said method comprising administering to ~~a~~ said subject ~~in need of such treatment or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formula (Ia), ~~(II) or (III)~~ wherein said compound of Formula (Ia) is:



(Ia)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;

R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

each R^2, R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio,

substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio;

each R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio;

and one or more ~~agonists or~~ antagonists of an Edg receptor.

36. (Currently amended) A method for treating ~~or preventing cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, cardiovascular diseases,~~ vasoconstriction~~, autoinmmune disorders or vascular occlusive disorders~~ in a subject in need of such treatment, said method comprising administering to ~~a~~ said subject ~~in need of such treatment or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formula (Ia), ~~(II) or (III)~~ wherein said compound of Formula (Ia) is:



(Ia)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;

R^1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

each R^2, R^3 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted

heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio;

each R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio;

and one or more drugs useful in treating ~~or preventing cancers, acute lung diseases, acute inflammatory exacerbation of chronic lung diseases, surface epithelial cell injury, cardiovascular diseases,~~ vasoconstriction[[,]] ~~autoimmune disorders or vascular occlusive disorders~~.

37. (Currently amended) The method of Claim **[[28]]** **1 or 2**, wherein the modulator is a compound of a formula that is selected from ~~the group consisting of~~:



101



102



105



106



107



108



109



110



111



112



113

and

38. (Withdrawn) The method of Claim **29**, wherein the modulator is a compound of formula



104

39. (Withdrawn) The method of Claim **30**, wherein the modulator is a compound of formula



103

40. (Withdrawn) The method of Claim **1** or **2**, wherein the biological activity is an immune response.

41. (Withdrawn) The method of Claim **40**, wherein the immune response is stimulated by SIP.

42. (Withdrawn, Currently amended) A method for treating ~~or preventing~~ a disorder in a subject, comprising administering to ~~a~~ said subject in need of such treatment ~~or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formulae (I), (II) or (III), wherein the compound of ~~structural formula~~ Formulae (I), (II) or (III) stimulates the immune system.

43. (Withdrawn) The method of Claim **42**, wherein the subject suffers from an inherited immune deficiency.

44. (Withdrawn, Currently amended) The method of Claim **42**, wherein the compound of ~~structural formula~~ Formulae (I), (II) or (III) is administered as an adjuvant to a vaccine.

45. (Withdrawn) The method of Claim **42**, wherein the subject is infected with a virus.

46. (Withdrawn) The method of Claim **45**, wherein the virus is selected from the group consisting of cytomegalovirus, herpes simplex virus I, herpes simplex virus II, influenza A virus, influenza B virus, hepatitis A virus, hepatitis C virus, hepatitis C virus, and human immunodeficiency virus.

47. (Withdrawn, Currently amended) A method for treating ~~or preventing~~ an immune disorder in a subject, comprising administering to ~~a~~ said subject in need of such treatment ~~or prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ Formulae (I), (II) or (III), wherein the immune disorder is characterized by inappropriate activation of the immune system.

48. (Withdrawn, Currently amended) The method of Claim **47**, wherein the compound of ~~structural formula~~ Formulae (I), (II) or (III) suppresses the immune system of the subject.

49. (Withdrawn) The method of Claim **48**, wherein the subject is afflicted with a disorder that is selected from the group consisting of systemic lupus erythematosus, rheumatic cardiatis, polymyosis, pemphigus, bullous dermatits herpetiformis, Stevens-Johnson syndrome, mycosis fungoides, dermatitis, ulcerative colitis, Crohn's disease, intractable sprue, idiopathic thrombocytopenic purpura, hemolytic anemia, erythroblastopenia, congenital hypoplastic anemia, osteoarthritis, rheumatoid arthritis, bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, multiple sclerosis, keratitis, irititis, irisocyclitis, chorioretinitis, choroiditis, optic neuritis, sarcoiodosis, Loeffler's syndrome, berylliosis, tuberculosis, sponylitis, tenosynovitis, psoriatic arthritis, and type I diabetes mellitus.

50. (Withdrawn) The method of Claim **48**, wherein the subject is the recipient of a transplanted cell, tissue, or organ.

51. (New) A method of treating vasoconstriction in a patient comprising:

administering to the patient a therapeutically effective amount of a modulator of an Edg-1 receptor wherein the modulator is a compound of Formula (Ib) is:



(Ib)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;

R^{11} is an aryl group;

each R^2 and R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylallcyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

52. (New) The method of claim **51**, wherein said aryl group in R^{11} is a heteroaryl group.

53. (New) The method of claim **52**, wherein said compound has the formula:



54. (New) The method of claim **53**, wherein R^2 is a substituted alkyl group.

55. (New) The method of claim **54**, wherein R^2 is said substituted alkyl group is $-CF_3$.

56. (New) The method of claim **55**, wherein n is 1.

57. (New) The method of claim **56**, wherein R^4 is a halo group.

58. (New) The method of claim **57**, wherein said halo group is chlorine.

59. (New) A method of treating vasoconstriction in a patient comprising:

administering to the patient a therapeutically effective amount of a modulator of an Edg-1 receptor wherein the modulator is a compound of Formula (Ic):



(Ic)

n is a member selected from the integers 0 to 5;

each R^4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylallcyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

60. (New) The method of claim **59**, wherein n is 1.

61. (New) The method of claim **60**, wherein R^4 is a halo group.

62. (New) The method of claim **61**, wherein said halo group is chlorine.

63. (New) A method of modulating an Edg-1 receptor mediated biological activity in a subject, comprising administering to the subject a therapeutically effective amount of a non-phospholipid modulator of the Edg-1 receptor, wherein the modulator is a compound of Formula (II):



(II)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

X is a member selected from the group consisting of O and S;

each R^1, R^2, R^3, R^4 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and

each R^6, R^7, R^8, R^9 and R^{10} is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

64. (New) A method of modulating an Edg-1 receptor mediated biological activity in a subject, comprising administering to the subject a therapeutically effective amount of a non-phospholipid modulator of the Edg-1 receptor, wherein the modulator is a compound of Formula (III):



(III)

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 1 to 4;

m is a member selected from the integers 1 to 4;

each X and Y is a member independently selected from the group consisting of C and N; and

each R^1, R^2, R^3, R^4 and R^5 is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.